Additionally, the ablation of ChREBP reduces the symptoms of DN, including glomerular hypertrophy, in mice with STZ-induced diabetes [46], suggesting that ChREBP may play an important role in the progression of DN. Here, MLXIPL is linked to liver dysplastic nodule.